Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate ...

Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT 2025 ...

Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ...

Precedence Research introduces its Advanced Cell and Gene Therapy Intelligence Platform, turning complex data into actionable ...

Tenaya Therapeutics reports positive preclinical data for TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, published in Nature Communications. Tenaya Therapeutics, Inc. has ...

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...